Health Canada has granted authorization for Foundayo, a daily oral medication from Eli Lilly designed for weight management. This new GLP-1 treatment offers a significant departure from the weekly injectable drugs that have dominated the market, providing a more convenient routine for many patients.

Who can use the new medication?

The pill is authorized for adults struggling with obesity. It is also approved for individuals who are overweight but suffer from at least one secondary health complication, such as high blood pressure or sleep apnea. Beyond weight management, the medication is also cleared to assist in the treatment of Type 2 diabetes.

How does this pill differ from injections?

Foundayo utilizes orforglipron, a type of non-peptide GLP-1 receptor agonist. Unlike the peptide-based injectables like Mounjaro or Ozempic, this medication consists of a smaller molecule. This structural difference allows the drug to be absorbed by the body through the digestive tract without being broken down.

Dr. Ehud Ur, a Vancouver-based endocrinologist, noted that the effectiveness for weight loss appears to be comparable to, or potentially even better than, current injectable options. While some patients may prefer the ease of a daily pill, doctors are still awaiting further research to determine if the drug provides the same heart-related benefits seen in other treatments in this class.

What to expect during the rollout

Eli Lilly expects the medication to be available at pharmacies across the country starting in January. While the convenience of a pill is a major step forward, users should be mindful of common side effects, which typically include nausea and vomiting.

  • Availability: Expected in pharmacies by January.
  • Current pill options: Novo Nordisk's Rybelsus is already in Canada but is restricted to diabetes management.
  • Future competition: A semaglutide-based oral weight-loss pill is also currently awaiting approval.

FAQ

Is Foundayo a replacement for all injections?

It serves as an oral alternative, though doctors will determine the best approach for each patient based on individual medical needs.

What are the most common side effects?

Patients frequently report gastrointestinal issues, most notably vomiting and nausea.